Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine
Safety and tolerability profile of rimegepant with up to one year of dosing in patients with migraine is consistent with previous Phase 1-3 clinical experience
No l... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, rimegepant, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news